New Zealand markets open in 8 hours 22 minutes

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
196.79-3.37 (-1.68%)
At close: 04:00PM EDT
197.89 +1.10 (+0.56%)
Pre-market: 07:00AM EDT
Show:
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2021
31/12/2020
31/12/2019
31/12/2018
Total revenue
884,245
844,287
492,853
219,750
74,908
Cost of revenue
146,762
140,144
78,052
25,062
1,802
Gross profit
737,483
704,143
414,801
194,688
73,106
Operating expenses
Research development
799,227
792,156
654,819
655,114
505,420
Selling general and administrative
652,912
620,639
588,420
479,005
382,359
Total operating expenses
1,452,139
1,412,795
1,243,239
1,134,119
887,779
Operating income or loss
-714,656
-708,652
-828,438
-939,431
-814,673
Interest expense
162,061
143,021
84,496
-
-
Total other income/expenses net
-105,481
-2,050
45,525
20,730
24,737
Income before tax
-978,567
-852,144
-855,600
-885,253
-760,674
Income tax expense
2,150
680
2,681
863
823
Income from continuing operations
-980,717
-852,824
-858,281
-886,116
-761,497
Net income
-980,717
-852,824
-858,281
-886,116
-761,497
Net income available to common shareholders
-980,717
-852,824
-858,281
-886,116
-761,497
Basic EPS
-
-7.20
-7.46
-8.11
-7.57
Diluted EPS
-
-7.20
-7.46
-8.11
-7.57
Basic average shares
-
118,451
114,986
109,264
100,590
Diluted average shares
-
118,451
114,986
109,264
100,590
EBITDA
-
-619,429
-696,669
-885,063
-808,238